Welcome to our dedicated page for ClearPoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro, Inc. reported that CEO and President Joseph Burnett acquired a grant of 147,275 restricted stock units. Each unit represents a contingent right to receive one share of CLPT common stock.
The restricted stock units vest over three years: 20% of the total shares on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning the award with multi-year executive retention and performance incentives.
ClearPoint Neuro filed an amended current report to add detailed financial information for its acquisition of IRRAS Holdings, Inc. The 8-K/A supplies IRRAS’s audited 2024 financial statements, unaudited 2025 interim results, and unaudited pro forma combined financials showing how the two businesses would look if reported together.
The company emphasizes that these pro forma figures are for informational purposes only and do not represent actual historical results or forecasts of future performance after the acquisition.
Bigger Capital Fund LP and related entities filed an amended Schedule 13G reporting their beneficial ownership of ClearPoint Neuro, Inc. common stock as of February 4, 2026. Bigger Capital and its general partner Bigger Capital Fund GP, LLC report beneficial ownership of 1,333,155 shares, or about 4.69% of the outstanding stock.
District 2 Capital Fund LP and its affiliated entities report beneficial ownership of 337,696 shares, or about 1.19%. Michael Bigger may be deemed to beneficially own about 7.8% of the common stock, including interests attributed through these funds and family holdings. The percentages are based on 28,423,308 shares outstanding as of October 27, 2025, and the filers certify the holdings are not for the purpose of changing or influencing control of ClearPoint Neuro.
ClearPoint Neuro, Inc. insider activity: a trust associated with CEO and President Joseph Burnett sold 2,943 shares of ClearPoint Neuro common stock on 01/26/2026 at a weighted average price of $15.57 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
After this sale, the Joseph M. Burnett Trust held 214,116 shares indirectly for Mr. Burnett, and he also held 11,565 shares directly. The sale price range was from $15.23 to $15.65 per share, and detailed trade breakdowns are available from the company or the SEC staff upon request.
A holder of CLPT common stock filed a notice to sell 2,943 shares under Rule 144. The shares are common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $46,146.24, and an approximate sale date of 01/26/2026 on the NASDAQ market. These 2,943 shares were acquired on 08/20/2023 as restricted stock units from the issuer, matching the amount now planned for sale. The filing notes that a related 10b5-1 plan already led to a prior sale of 20,000 common shares on 01/09/2026 for $322,404 in gross proceeds, and states that total common shares outstanding are 28,423,308.
ClearPoint Neuro, Inc. has filed a resale prospectus covering up to 1,312,570 shares of its common stock that may be sold from time to time by former IRRAS Holdings, Inc. stockholders. ClearPoint is not selling shares in this offering and will receive no proceeds from any sales.
The registered shares were or will be issued as part of ClearPoint’s November 20, 2025 acquisition of IRRAS, a neurocritical care medical technology company. Consideration for the merger included $5,000,000 in cash and 1,119,404 ClearPoint shares, plus potential earnout payments. The 1,312,570 registered shares consist of 1,109,401 merger shares plus up to 203,169 holdback shares that may be released if no post-closing adjustments or indemnity claims reduce them.
ClearPoint is a commercial-stage medical device company focused on minimally invasive neurosurgery, including its ClearPoint Navigation System, operating-room focused SmartFrame platforms, and the ClearPoint Prism Neuro Laser Therapy System. Its biologics and drug delivery partnerships support more than 60 gene and cell therapy programs targeting direct delivery into the brain.
ClearPoint Neuro, Inc. has filed a resale registration covering up to 1,312,570 shares of common stock that were issued or may be issued to former owners of IRRAS Holdings, Inc. in connection with a merger completed on November 20, 2025. These shares include 1,109,401 merger shares and up to 203,169 holdback shares that may be released if post-closing adjustment and indemnification conditions are met.
The company is not selling any shares under this prospectus and will not receive proceeds from sales by the selling stockholders. IRRAS adds a neurocritical care product focus to ClearPoint’s neurosurgical and biologics delivery platforms. As context, ClearPoint had 28,423,308 common shares outstanding as of October 27, 2025, and its stock last traded at $15.65 per share on January 12, 2026.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported option exercises and a stock sale. On 01/09/2026 he exercised 20,000 stock options with a $2.50 exercise price, receiving 20,000 shares of common stock, and on the same day sold 20,000 common shares at a weighted average price of $16.12 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025. After these transactions, he directly holds 11,565 common shares and 330,000 stock options, and indirectly holds 217,059 common shares through the Joseph M. Burnett Trust dated 10/20/2022.
ClearPoint Neuro, Inc. furnished an update on its recent performance by disclosing that it has issued a press release with preliminary, unaudited financial results for the fourth quarter ended December 31, 2025. The company used a current report to make investors aware of this earnings-related press release, which is included as an exhibit. The preliminary figures are described only in the press release itself, which is referenced but not detailed here.